Rivastigmin ІC (rivastigmine) capsules 3 mg. №30

Description

Rivastigmin ІC (rivastigmine) capsules 3 mg. №30

Composition

active substance: rivastigmine;

1 capsule contains rivastigmine hydrotartrate 2.4 mg (in terms of rivastigmine 1.5 mg), rivastigmine hydrotartrate 4.8 mg (in terms of rivastigmine 3 mg), rivastigmine hydrotartrate 7.2 mg (in terms of rivastigmine 4.5 mg ) or rivastigmine hydrotartrate 9.6 mg (in terms of rivastigmine 6 mg);

excipients: hypromellose (hydroxypropylmethylcellulose), colloidal anhydrous silicon dioxide, microcrystalline cellulose, magnesium stearate, gelatin, titanium dioxide (E 171).

Medicinal form

Capsules.

Main physicochemical properties: opaque hard gelatin capsules, white body, white cap; the contents of the capsules are white to almost white powder.

Pharmacotherapeutic group

Psychoanaleptics. Drugs used in dementia. Cholinesterase inhibitors. Rivastigmine.
ATX code N06D A03.

Pharmacological properties

This drug is one of the psychoanaleptic drugs used to treat dementia (senile dementia).
The main active ingredient is rivastigmine. The specified pharmaceutical component, when used appropriately, has the ability to reduce the intensity of manifestations of dementia. Rivastigmine is a cholinesterase enzyme inhibitor. Its use promotes the transmission of cholinergic nerve pathways, while inhibiting the degradation of acetylcholines, which are released from cholinergic neurons, which are characterized by intact function. As a consequence, the use of rivastigmine helps to alleviate the lack of cognitive functions of the brain, which is caused by disorders of cholinergic transmission of nerve impulses, in the case of dementia, which is caused by parkinsonism or Alzheimer’s syndrome.
Rivastigmine interacts with target enzymes, forming a covalent complex that briefly inactivates the enzymes.
The effect of the drug is dose-dependent.

Indications

The specified pharmaceutical agent is used for the symptomatic treatment of mild to moderate dementia caused by Alzheimer’s disease.
Also used for the symptomatic treatment of dementia in patients with idiopathic Parkinson’s disease (mild to moderate).

Contraindications

The drug Rivastigmin ІC in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.
Reception is contraindicated in case of severe liver dysfunctions.
Caution should be exercised if anesthesia is required during treatment with rivastigmine. this substance enhances the effect of muscle relaxants.
Also, it should not be used simultaneously with other cholinomimetics, anticholinergic drugs.
It is important to exercise caution when used concomitantly with beta-blockers, antipsychotic drugs.
Not used in pediatrics.

Application during pregnancy and lactation

The drug should not be administered during pregnancy.
If there is a need to use this drug during lactation, then breastfeeding should be suspended for this period.

Method of administration and dosage

Rivastigmin ІC is administered orally with water without chewing. Treatment begins exclusively under the supervision of an experienced attending physician and with constant monitoring of the patient’s well-being and care.
The recommended dosage is 1 tablet 2 times a day, morning and evening, with food.
Start with a minimum dose of 1.5 mg rivastigmine. If tolerance is good, then the dose can be increased to 3 mg rivastigmine per dose. All subsequent dosage increases should be based on drug tolerance levels.
The maximum dosage is 6 mg rivastigmine 2 times a day. The maximum duration of treatment is 6 months. The maintenance dosage is 3 to 6 mg of rivastigmine per dose.
If after 3 months there is no improvement in the condition, treatment with this drug should be discontinued.
Correction of dosage and duration of treatment is determined individually by the attending physician.

Overdose

Overdose can cause:

• miosis, hot flashes;
• digestive disorders;
• bradycardia, bronchospasm;
• lacrimation, hypotension;
• tremors, hallucinations, malaise.

Gastric lavage is recommended, in case of severe overdose – atropine.

Side effects

The drug is usually well tolerated. At the same time, side effects may occur during treatment with this drug. In particular:

• nausea, diarrhea, vomiting, dyspepsia, itching, allergic urticaria, other manifestations of allergic reactions;
• agitation, nightmares, anxiety, aggression;
• depression, insomnia;
• angina pectoris, arrhythmia;
• stomach ulcer, 12-person intestine, pancreatitis;
• decreased appetite, hepatitis;
• asthenia, fatigue, tremor, dystonia;
• sweating, anorexia, dehydration.